{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:03:14Z","timestamp":1793642594513,"version":"4.5.1"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Bladder cancer (BCa) is one of the most common malignant tumors that cause death. Approximately 75%\u201385% of BCa develop into non-muscle-invasive bladder cancer (NMIBC). Bacillus Calmette-Gu\u00e9rin (BCG) is the gold standard for avoiding cystectomy in the treatment of NMIBC. Unfortunately, up to 30% of patients do not respond to BCG treatment, and up to 70% of BCG responders relapse. The United States Food and Drug Administration (FDA) approved valrubicin (1998) and pembrolizumab (2020) for the treatment of BCG-unresponsive (BCGu) NMBIC. However, the complete remission rate for valrubicin and pembrolizumab was only 16% and 40.6%, respectively. ALT-803 (N-803) is an IL-15 superagonist and reduces tumor burden by promoting the proliferation and activation of NK cells and CD8<jats:sup>+<\/jats:sup> T cells. The FDA received (23 May 2022) and accepted to review (28 July 2022) the marketing submission of ALT-803 plus BCG for the treatment of BCGu NMIBC. However, the FDA previously rejected the application for oportuzumab monatox (OM) due to a lack of data comparing it with pembrolizumab on August 20, 2021. Interestingly, the clinical efficacy and safety of ALT-803 were higher than that of pembrolizumab and OM, suggesting that ALT-803 may be approved by FDA. This review aims to further knowledge of the preclinical and clinical evidence of ALT-803 in the treatment of NMIBC and discuss its translational potential.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1040669","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T07:16:44Z","timestamp":1668064604000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential"],"prefix":"10.3389","volume":"13","author":[{"given":"Wujun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongming","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-020-03474-8","article-title":"Immunotherapy in non-Muscle-Invasive bladder cancer: Current status and future directions","volume":"39","author":"Pfail","year":"2021","journal-title":"World J Urol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11934-018-0852-6","article-title":"Current clinical trials in non-muscle invasive bladder cancer","volume":"19","author":"Nykopp","year":"2018","journal-title":"Curr Urol Rep"},{"key":"B3","unstructured":"Bacillus calmette-Gu\u00e9rin-Unresponsive nonmuscle invasive bladder cancer: Developing drugs and biologics for treatment guidance for industry2018"},{"key":"B4","unstructured":"FDA Approves pembrolizumab for bcg-unresponsive, high-risk non-muscle invasive bladder cancer2020"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/srep27455","article-title":"Local immune stimulation by intravesical instillation of baculovirus to enable bladder cancer therapy","volume":"6","author":"Ang","year":"2016","journal-title":"Sci Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of urology guidelines on non-Muscle-Invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk M","year":"2022","journal-title":"Eur Urol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1464-410X.2011.10880.x","article-title":"Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (Nmibc): A systematic review","volume":"109","author":"Shelley","year":"2012","journal-title":"BJU Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2082869","article-title":"Emerging treatment landscape of non-muscle invasive bladder cancer","volume":"22","author":"Valenza C","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2017.08.010","article-title":"The potential and promise of il-15 in immuno-oncogenic therapies","volume":"190","author":"Robinson","year":"2017","journal-title":"Immunol Lett"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2022.2046466","article-title":"Evolution of immunotherapy in the treatment of non-Muscle-Invasive bladder cancer","volume":"22","author":"Lobo","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2016.03.007","article-title":"Antitumor activity of recombinant bacille calmette-guerin secreting interleukin-15-Ag85b fusion protein against bladder cancer","volume":"35","author":"Takeuchi","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2017.04.015","article-title":"Intravesical alt-803 for bcg-unresponsive bladder cancer - a case report","volume":"14","author":"Huang","year":"2017","journal-title":"Urol Case Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-1778-6","article-title":"Effectiveness of two different dose administration regimens of an il-15 superagonist complex (Alt-803) in an orthotopic bladder cancer mouse model","volume":"17","author":"Furuya","year":"2019","journal-title":"J Transl Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1950531","article-title":"Immunotherapy of high risk non-muscle invasive bladder cancer","volume":"14","author":"Ahdoot","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1055\/a-1677-0952","article-title":"[Adjuvant instillation therapy for non-muscle invasive bladder cancer - beyond bcg and mitomycin c]","volume":"53","author":"Gakis","year":"2022","journal-title":"Aktuelle Urol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/cancers14030694","article-title":"From interferon to checkpoint inhibition therapy-a systematic review of new immune-modulating agents in bacillus calmette-gu\u00e9rin (Bcg) refractory non-Muscle-Invasive bladder cancer (Nmibc)","volume":"14","author":"Deininger S","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B17","unstructured":"Sesen bio withdraws eu application for cancer drug FDA just turned down2021"},{"key":"B18","unstructured":"SingletonS\n          Immunitybio announces FDA acceptance of biologics license application for n-803 in bcg-unresponsive non-Muscle-Invasive bladder cancer carcinoma in situ2022"},{"key":"B19","unstructured":"HealthcareG\n          Immunitybio moves closer to its first marketed drug but approval is questionable2022"},{"key":"B20","unstructured":"HermanG\n          Immunitybio\u2019s Patrick soon-shiong discusses quest to orchestrate nk and T cells"},{"key":"B21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2326-6066.CIR-15-0093-T","article-title":"Comparison of the superagonist complex, alt-803, to Il15 as cancer immunotherapeutics in animal models","volume":"4","author":"Rhode","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2017.12.003","article-title":"Evaluation of the biological activities of the il-15 superagonist complex, alt-803, following intravenous versus subcutaneous administration in murine models","volume":"107","author":"Liu","year":"2018","journal-title":"Cytokine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e96705","DOI":"10.1371\/journal.pone.0096705","article-title":"Intravesical alt-803 and bcg treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and nk cell expansion","volume":"9","author":"Gomes-Giacoia","year":"2014","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-311456","article-title":"Safety (Toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human il-15 in rhesus macaques","volume":"117","author":"Waldmann","year":"2011","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-189266","article-title":"Safety and immunologic effects of il-15 administration in nonhuman primates","volume":"114","author":"Berger","year":"2009","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.21953","article-title":"Phosphate moiety in fda-approved pharmaceutical salts and prodrugs","volume":"83","author":"Fulmali A","year":"2022","journal-title":"Drug Dev Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-020-03586-1","article-title":"Prognostic value of albumin to globulin ratio in non-Muscle-Invasive bladder cancer","volume":"39","author":"Quhal","year":"2021","journal-title":"World J Urol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100066","article-title":"Phase I trial characterizing the pharmacokinetic profile of n-803, a chimeric il-15 superagonist, in healthy volunteers","volume":"208","author":"Rubinstein","year":"2022","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/j.juro.2017.02.497","article-title":"Mp15-12 phase ib trial of alt-803, an il-15 superagonist, plus bacillus calmette guerin (Bcg) for the treatment of bcg-naive patients with non-muscleinvasive bladder cancer (Nmibc)","volume":"197","author":"Rosser CJ","year":"2017","journal-title":"J Urol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1912885","article-title":"Safety, tolerability, and long-term clinical outcomes of an il-15 analogue (N-803) admixed with bacillus calmette-guerin (Bcg) for the treatment of bladder cancer","volume":"10","author":"Rosser","year":"2021","journal-title":"Oncoimmunology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4508","article-title":"Final clinical results of pivotal trial of il-15r\u03b1fc superagonist n-803 with bcg in bcg-unresponsive cis and papillary nonmuscle-invasive bladder cancer (Nmibc)","volume":"40","author":"Chamie","year":"2022","journal-title":"J Clin Oncol"},{"key":"B32","unstructured":"SingletonS\n          Immunitybio announces quilt trial results for bcg-unresponsive bladder cancer and advanced metastatic pancreatic cancer at the 2022 American society of clinical oncology annual meeting2022"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.510","article-title":"Phase Ii\/Iii clinical results of il-15r\u03b1fc superagonist n-803 with bcg in bcg-unresponsive non-muscle invasive bladder cancer (Nmibc) carcinoma in situ (Cis) patients","volume":"39","author":"Chamie","year":"2021","journal-title":"J Clin Oncol"},{"key":"B34","unstructured":"Novel il-15 superagonist n-803 hits high complete response rate in bcg-unresponsive nmibc\n            VirgilH\n          2021"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000269","article-title":"Immunogenomic analysis of exceptional responder to alt-803 (Il-15 analogue) in bcg unresponsive nonmuscle invasive bladder cancer: A case series and review of the literature","volume":"42","author":"Huang","year":"2019","journal-title":"J Immunother"},{"key":"B36","doi-asserted-by":"publisher","first-page":"797","DOI":"10.18553\/jmcp.2021.27.6.797","article-title":"The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for bcg-unresponsive non-Muscle-Invasive bladder cancer","volume":"27","author":"Beinfeld M","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000000863","article-title":"The current landscape of salvage therapies for patients with bacillus calmette-guerin unresponsive nonmuscle invasive bladder cancer","volume":"31","author":"Packiam","year":"2021","journal-title":"Curr Opin Urol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.451","article-title":"Pembrolizumab for the treatment of patients with high-risk (Hr) non-Muscle-Invasive bladder cancer (Nmibc) unresponsive to bacillus calmette-gu\u00e9rin: Extended follow-up of keynote-057 cohort a","volume":"39","author":"Balar","year":"2021","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-Muscle-Invasive bladder cancer unresponsive to bcg (Keynote-057): An open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar AV","year":"2021","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000823.02","article-title":"Pd03-02 phase 3 results of vicinium in bcg-unresponsive non-muscle invasive bladder cancer","volume":"203","author":"Shore","year":"2020","journal-title":"J Urol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2021.02.007","article-title":"Preclinical models for bladder cancer research","volume":"35","author":"Zhu S","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2018.08.015","article-title":"Background and update for S1602 \"a phase iii randomized trial to evaluate the influence of bcg strain differences and T cell priming with intradermal bcg before intravesical therapy for bcg-naive high-grade non-Muscle-Invasive bladder cancer","volume":"4","author":"Svatek","year":"2018","journal-title":"Eur Urol Focus"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20680","article-title":"Analyses of functions of an anti-Pd-L1\/Tgfbetar2 bispecific fusion protein (M7824)","volume":"8","author":"Jochems","year":"2017","journal-title":"Oncotarget"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.003","article-title":"Bintrafusp Alfa, a bifunctional fusion protein targeting tgf-beta and pd-L1, in second-line treatment of patients with nsclc: Results from an expansion cohort of a phase 1 trial","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2653","article-title":"Phase I trial of M7824 (Msb0011359c), a bifunctional fusion protein targeting pd-L1 and tgfbeta, in advanced solid tumors","volume":"24","author":"Strauss","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.09.027","article-title":"Anti-Pd-L1\/Tgfbetar2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis","volume":"36","author":"Grenga","year":"2018","journal-title":"Urol Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2011.013","article-title":"Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model","volume":"22","author":"Matsumoto","year":"2011","journal-title":"Hum Gene Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.intimp.2014.06.008","article-title":"P21waf1 mediates the il-15-Induced migration and invasion of human bladder cancer 5637 cells Via the Erk1\/2\/Nf-Kappab\/Mmp-9 pathway","volume":"22","author":"Park","year":"2014","journal-title":"Int Immunopharmacol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014789","article-title":"N-803: A double-edged sword in haplo-nk therapy","volume":"139","author":"Pende","year":"2022","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1040669\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T07:16:49Z","timestamp":1668064609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1040669\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2022.1040669"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1040669","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]},"article-number":"1040669"}}